Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer
This study is currently recruiting participants.
Verified October 2012
by Eisai Inc.
Study NCT01432886 Information provided by Eisai Inc.
First Received on September 12, 2011. Last Updated on October 15, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
More general conditions related to this trial
Neoplasms by Site
Interventions listed in this trial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Molecular Mechanisms of Pharmacological Action
Sponsors listed in this trial
Eisai Co., Ltd.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers